Canada markets closed

AbbVie Inc. (ABBV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
178.99+0.18 (+0.10%)
At close: 04:00PM EST
178.90 -0.09 (-0.05%)
After hours: 06:40PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close178.81
Bid178.75 x 800
Ask179.03 x 800
Day's Range176.99 - 179.53
52 Week Range130.96 - 179.79
Avg. Volume5,438,127
Market Cap316.18B
Beta (5Y Monthly)0.54
PE Ratio (TTM)65.81
EPS (TTM)2.72
Earnings DateApr 25, 2024 - Apr 29, 2024
Forward Dividend & Yield6.20 (3.47%)
Ex-Dividend DateApr 12, 2024
1y Target Est181.38
  • GlobeNewswire

    Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

    NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A. The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines. CKDB-501A is a novel BoNT/A neuromodulator

  • PR Newswire

    AbbVie to Present at the TD Cowen 44th Annual Health Care Conference

    AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:10 a.m. Central time.

  • PR Newswire

    U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

    AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. If approved, epcoritamab-bysp (EPKINLY®) will be the first and only subcutaneous bispecific antibody to treat adults with R/R